Volume control in peritoneal dialysis patients: Role of new dialysis solutions

Blood Purification

Volumn 22, Issue 1, 2004, Pages 44-54

  Lameire, Norbert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Biocompatibility; Glucose degradation products; Left ventricular hypertrophy; Peritoneal dialysis; Ultrafiltration failure; Volume control

Indexed keywords

BICARBONATE; BUFFER; GLUCOSE DEGRADATION PRODUCT; GLUCOSE POLYMER; ICODEXTRIN; LACTIC ACID; SODIUM;

BIOCOMPATIBILITY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DIALYSATE; GLYCATION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERTENSION; LIQUID; MEMBRANE; METABOLIC ACIDOSIS; PAIN; PERITONEAL DIALYSIS; PH; PREVALENCE; PRIORITY JOURNAL; REVIEW; ULTRAFILTRATION; UREMIA;

ACIDOSIS; BICARBONATES; BLOOD VOLUME; DOUBLE-BLIND METHOD; GLUCANS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMODIALYSIS SOLUTIONS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; LACTATES; MULTICENTER STUDIES; PAIN; PERITONEAL DIALYSIS; PERITONITIS; RANDOMIZED CONTROLLED TRIALS; SODIUM; TREATMENT FAILURE;

EID: 0942268187     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074923     Document Type: Review

References (109)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
2. Dionisio P, Valenti M, Bergia R, Caramello E, Stramignoni E, Berto IM, Pellerey M, Bajardi P: Influence of the hydration state on blood pressure values in a group of patients on regular maintenance hemodialysis. Blood Purif 1997; 15:25-33.
3. Gunal AI, Duman S, Ozkahya M, Toz H, Asci G, Akcicek F, Basci A: Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001;37:588-593.
4. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM: Aortic and large artery compliance in end-stage renal failure. Kidney Int 1990;37:137-142.
5. Lameire N, Vanbiesen W: Importance of volume and blood pressure control in peritoneal dialysis patients. Perit Dial Int 2001;21:206-211.
6. Plum J, Schoenicke G, Kleophas W, Kulas W, Steffens F, Azem A, Grabensee B: Comparison of body fluid distribution between chronic haemodialysis and peritoneal dialysis patients as assessed by biophysical and biochemical methods. Nephrol Dial Transplant 2001;16:2378-2385.
7. Konings CJAM, Kooman JP, Schonck M, Dammers R, Cherix E, Palmans Meulemans AP, Hoeks APG, van Kreel B, Gladziwa U, van der Sande FM, Leunissen KLM: Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002;22:477-487.
8. Koc M, Toprak A, Tezcan H, Bihorac A, Akoglu E, Ozener IC: Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patients. Nephrol Dial Transplant 2002;17:1661-1666.
9. Cocchi R, Esposti ED, Fabbri A, Lucatello A, Sturani A, Quarello F, Boero R, Bruno M, Dadone C, Favazza A, Scanziani R, Tommasi A, Giangrande A: Prevalence of hypertension in patients on peritoneal dialysis: Results of an Italian multicentre study. Nephrol Dial Transplant 1999;14:1536-1540.
10. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D: Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998;9:1285-1292.
11. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-2162.
12. Heaf J: CAPD adequacy and dialysis morbidity: Detrimental effect of a high peritoneal equilibration rate. Ren Fail 1995;17:575-587.
13. Davies SJ, Phillips L, Russell GI: Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998;13:962-968.
14. Tzamaloukas AH, Saddler MC, Murata GH, Malhotra D, Sena P, Simon D, Hawkins KL, Morgan K, Nevarez M, Wood B: Symptomatic fluid retention in patients on continuous peritoneal dialysis. J Am Soc Nephrol 1995;6:198-206.
15. Amann K, Mandelbaum A, Schwarz U, Ritz E: Hypertension and left ventricular hypertrophy in the CAPD patient. Kidney Int Suppl 1996;56:S37-S40.
16. Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Erturk S, Duman N, Karatan O, Ertug AE: Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001;60:767-776.
17. Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11:498-506.
18. Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G, Kawaguchi Y, Kawanishi H, Korbet S, Krediet R, Lindholm B, Oreopoulos D, Rippe B, Selgas R: Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000;20(suppl 4):S5-S21.
19. Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT: Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 1997;17:144-150.
20. Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, Borrego F, Jimenez C, Del Peso G, De Alvaro F: Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 1994; 23:64-73.
21. Heimburger O, Wang T, Lindholm B: Alterations in water and solute transport with time on peritoneal dialysis. Perit Dial Int 1999;19(suppl 2):S83-S90.
22. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
23. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B: Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990;38:495-506.
24. Mactier RA, Khanna R, Twardowski ZJ, Nolph KD: Ultrafiltration failure in continuous ambulatory peritoneal dialysis due to excessive peritoneal cavity lymphatic absorption. Am J Kidney Dis 1987;10:461-466.
25. Monquil MC, Imholz AL, Struijk DG, Krediet RT: Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int 1995;15:42-48.
26. Goffin E, Combet S, Jamar F, Cosyns JP, Devuyst O: Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport. Am J Kidney Dis 1999;33:383-388.
27. Krediet RT, Lindholm B, Rippe B: Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000;20(suppl 4):S22-S42.
28. Mortier S, De Vriese AS, Lameire N: Recent concepts in the molecular biology of the peritoneal membrane - implications for more bio-compatible dialysis solutions. Blood Purif 2003;21:14-23.
29. De Vriese AS, Mortier S, Lameire NH: Glucotoxicity of the peritoneal membrane: The case for VEGF. Nephrol Dial Transplant 2001;16:2299-2302.
30. De Vriese AS, Mortier S, Lameire NH: Neoangiogenesis in the peritoneal membrane: Does it play a role in ultrafiltration failure? Nephrol Dial Transplant 2001;16:2143-2145.
31. De Vriese AS, Mortier S, Lameire NH: What happens to the peritoneal membrane in long-term peritoneal dialysis? Perit Dial Int 2001; 21(suppl 3):S9-S18.
32. Devuyst O: Molecular mechanisms involved in the peritoneal membrane exposed to peritoneal dialysis. Nefrologia 2003;23(suppl 3):32-37.
33. Gillerot G, Devuyst O: Molecular mechanisms modifying the peritoneal membrane exposed to peritoneal dialysis. Clin Nephrol 2003;60:1-6.
34. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
35. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K, Horiuchi S: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999;14:1541-1549.
36. Park MS, Lee HA, Chu WS, Yang DH, Hwang SD: Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 2000;20:452-460.
37. Schmidt AM, Yan SD, Wautier EL, Stern D: Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-497.
38. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, Danze PM, Dequiedt P: AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002;61:148-156.
39. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH: Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003;14:2109-2118.
40. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, Gauldie J: Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002;13:721-728.
41. Devuyst O, Topley N, Williams JD: Morphological and functional changes in the dialysed peritoneal cavity: Impact of more biocompatible solutions. Nephrol Dial Transplant 2002; 17(suppl 3):12-15.
42. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, Lameire N, Devuyst O: Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001;12:2146-2157.
43. Craig KJ, Topley N, Williams JT, Williams JD: Morphological changes in the peritoneal membrane of patients on peritoneal dialysis correlate with total glucose exposure and with peritonitis rates (abstract). Perit Dial Int 2002;22:S24.
44. Jorres A, Gahl GM, Frei U: Peritoneal dialysis fluid biocompatibility: Does it really matter? Kidney Int Suppl 1994;48:S79-S86.
45. Topley N: Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions. Adv Ren Replace Ther 1998;5:179-184.
46. Struijk DG, Douma CE: Future research in peritoneal dialysis fluids. Semin Dial 1998;11:207-212.
47. Fussholler A, zur Nieden S, Grabensee B, Plum J: Peritoneal fluid and solute transport: Influence of treatment time, peritoneal dialysis modality, and peritonitis incidence. J Am Soc Nephrol 2002;13:1055-1060.
48. Fussholler A, Grabensee B, Plum J: Effluent CA 125 concentration in chronic peritoneal dialysis patients: Influence of PD duration, peritoneal transport and PD regimen. Kidney Blood Press Res 2003;26:118-122.
49. de Fijter CW, Verbrugh HA, Oe LP, Peters ED, van der MJ, Donker AJ, Verhoef J: Peritoneal defense in continuous ambulatory versus continuous cyclic peritoneal dialysis. Kidney Int 1992;42:947-950.
50. Duwe AK, Vas SI, Weatherhead JW: Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. Infect Immun 1981;33: 130-135.
51. Passlick-Deetjen J, Schaub TP, Schilling H: Solutions for APD: Special considerations. Semin Dial 2002;15:407-413.
52. Feriani M, Kirchgessner J, La GG, Passlick-Deetjen J: Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998;54:1731-1738.
53. Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M, Greiner C, Boswald M, Klaus G, Passlick-Deetjen J, Schaefer F: Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. Kidney Int 2002;61:1527-1536.
54. Haas S, Schmitt CP, Schaub TP, Schaefer F: Use of pH-neutral, bicarbonate buffered PD fluids in children on APD: Results of a randomized crossover trial (abstract). Perit Dial Int 2002;22:S71.
55. Otte K, Gonzalez MT, Bajo MA, Del Peso G, Heaf J, Garcia EG, Sanchez Tomero JA, Dieperink H, Povlsen J, Hopwood AM, Divino Filho JC, Faict D: Clinical experience with a new bicarbonate (25 mmol/l)/lactate (10 mmol/l) peritoneal dialysis solution. Perit Dial Int 2003;23:138-145.
56. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, Wrege U, Grontoft KC, Larsson R, Berglund J, Tranaeus AP, Faict D: Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998;53:1061-1067.
57. Wieslander AP, Andren A, Martinson E, Kjellstrand P, Hultqvist M: Toxicity of effluent peritoneal dialysis fluid. Adv Perit Dial 1993;9:31-35.
58. Wieslander AP, Nordin MK, Kjellstrand PT, Boberg UC: Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 1991;40:77-79.
59. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000;11:729-739.
60. Witowski J, Jorres A, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Bender TO, Passlick-Deetjen J, Breborowicz A: Glucose degradation products in peritoneal dialysis fluids: Do they harm? Kidney Int Suppl 2003;84:S148-S151.
61. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12: 2434-2441.
62. Liberek T, Topley N, Jorres A, Petersen MM, Coles GA, Gahl GM, Williams JD: Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993;65:260-265.
63. Douvdevani A, Rapoport J, Konforty A, Yulzari R, Moran A, Chaimovitz C: Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. J Am Soc Nephrol 1995;6:207-213.
64. Lage C, Pischetsrieder M, Aufricht C, Jorres A, Schilling H, Passlick-Deetjen J: First in vitro and in vivo experiences with Stay-Safe Balance, a pH-neutral solution in a dual-chambered bag. Perit Dial Int 2000;20(suppl 5):S28-S32.
65. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, Pischetsrieder M: In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001;280:1408-1414.
66. Passlick-Deetjen J, Pischetsrieder M, Witowski J, Bender TO, Jorres A, Lage C: In vitro superiority of dual-chambered peritoneal dialysis solution with possible clinical benefits. Perit Dial Int 2001;21(suppl 3):S96-S101.
67. Tauer A, Schmitt R, Knerr T, Schaub TP, Lage C, Passlick-Deetjen J, Pischetsrieder M: Formation of the glucose degradation product 3-deoxyglucosone and other carbonyl compounds in single- or double-chamber peritoneal dialysis fluids (abstract). Perit Dial Int 2000;20:142.
68. Jorres A: Glucose degradation products in peritoneal dialysis: From bench to bedside. Kidney Blood Press Res 2003;26:113-117.
69. Passlick-Deetjen J, Lage C: Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system. Perit Dial Int 2000;20(suppl 2):S42-S47.
70. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
71. Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, Uchida K, Saito A, Van Ypersele DS, Kurokawa K: Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000;58:425-435.
72. Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire NH: Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: Role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002;13:480-489.
73. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, Lameire NH: Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003;14:1296-1306.
74. Wieczorowska-Tobis K, Polubinska A, Schaub TP, Schilling H, Wisniewska J, Witowski J, Passlick-Deetjen J, Breborowicz A: Influence of neutral-pH dialysis solutions on the peritoneal membrane: A long-term investigation in rats. Perit Dial Int 2001;21(suppl 3):S108-S113.
75. Imholz AL, Koomen GC, Struijk DG, Arisz L, Krediet RT: Fluid and solute transport in CAPD patients using ultralow sodium dialysate. Kidney Int 1994;46:333-340.
76. Leypoldt JK, Charney DI, Cheung AK, Naprestek CL, Akin BH, Shockley TR: Ultrafiltration and solute kinetics using low sodium peritoneal dialysate. Kidney Int 1995;48:1959-1966.
77. Nakayama M, Yokoyama K, Kubo H, Matsumoto H, Hasegawa T, Shigematsu T, Kawaguchi Y, Sakai O: The effect of ultra-low sodium dialysate in CAPD. A kinetic and clinical analysis. Clin Nephrol 1996;45:188-193.
78. 3 solution with low sodium concentration over standard lactate solutions for acute peritoneal dialysis. Adv Perit Dial 1997;13:179-182.
79. Freida PH, Issad B: Impact of a low sodium dialysate on usual parameters of cardiovascular outcome of anuric patients during APD (abstract). Perit Dial Int 1998;18:124.
80. Ortega O, Gallar P, Carreno A, Gutierrez M, Rodriguez I, Oliet A, Vigil A, Gimenez E: Peritoneal sodium mass removal in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis: Influence on blood pressure control. Am J Nephrol 2001;21:189-193.
81. Rippe B, Rosengren BI, Venturoli D: The peritoneal microcirculation in peritoneal dialysis. Microcirculation 2001;8:303-320.
82. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen FD, Bro S, Friedberg M, Wieslander A: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-357.
83. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, Williams JD, Coles GA, Topley N: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001;59:1529-1538.
84. Zhang X, Niwa T, Bosselmann HP, Mettang T, Sulowicz W, Stompor T, Lage C, Passlick-Deetjen J, Pischetsrieder M: Serum imidazolone in CAPD patients treated with the new dual-chambered PD fluid Balance. Perit Dial Int 2002;22:S18.
85. Smit W, Pannekeet MM, Struijk DG, Krediet RT: Treatment of ultrafiltration failure with non-glucose dialysis solutions in patients with and without peritoneal sclerosis; in Smit W (ed): Various Aspects of Peritoneal Water Transport; doctoral thesis, s'Graveland, 2003, pp 159-174.
86. Vanbiesen W, Boer W, Degreve B, Dequidt C, Vijt D, Faict D, Lameire N: A randomized prospective clinical trial with a 0.6% aminoacid/ 1.4% glycerol peritoneal dialysis solution. Perit Dial Int, submitted.
87. Stoenoiu MS, Ni J, Verkaeren C, Debaix H, Jonas JC, Lameire N, Verbavatz JM, Devuyst O: Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat peritoneum. J Am Soc Nephrol 2003;14:555-565.
88. Van Biesen W, Vanholder R, Lameire N: Recent developments in osmotic agents for peritoneal dialysis. Adv Ren Replace Ther 1998;5:218-231.
89. Mistry CD, Gokal R, Peers E: A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994;46:496-503.
90. Mistry CD, Gokal R: Can ultrafiltration occur with a hypo-osmolar solution in peritoneal dialysis?: The role for 'colloid' osmosis. Clin Sci (Lond) 1993;85:495-500.
91. de Fijter CW, Verbrugh HA, Oe LP, Heezius E, Donker AJ, Verhoef J, Gokal R: Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993;21:411-418.
92. Liberek T, Topley N, Mistry CD, Coles GA, Morgan T, Quirk RA, Williams JD: Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 1993;13:104-111.
93. Jorres A, Gahl GM, Topley N, Neubauer A, Ludat K, Muller C, Passlick-Deetjen J: In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant 1994;9:785-790.
94. Wolfson M, Ogrinc F, Mujais S: Review of clinical trial experience with icodextrin. Kidney Int Suppl 2002;81:S46-S52.
95. Wilkie ME, Plant MJ, Edwards L, Brown CB: Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival. Perit Dial Int 1997;17:84-87.
96. Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B, Peeters J, Freida P, Struijk DG, Krediet RT, Grabensee B, Tranaeus A, Filho JC: Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002;39:862-871.
97. Lam-Po-Tang MK, Bending MR, Kwan JT: Icodextrin hypersensitivity in a CAPD patient. Perit Dial Int 1997;17:82-84.
98. Fletcher S, Stables GA, Turney JH: Icodextrin allergy in a peritoneal dialysis patient. Nephrol Dial Transplant 1998;13:2656-2658.
99. Pinerolo MC, Porri MT, D'Amico G: Recurrent sterile peritonitis at onset of treatment with icodextrin solution. Perit Dial Int 1999;19:491-492.
100. Heering P, Brause M, Plum J, Grabensee B: Peritoneal reaction to icodextrin in a female patient on CAPD. Perit Dial Int 2001;21:321-322.
101. Reichel W, Schulze B, Dietze J, Mende W: A case of sterile peritonitis associated with icodextrin solution. Perit Dial Int 2001;21:414-415.
102. Goffin E, Tintillier M, Cosyns JP, Devuyst O: Sterile chemical peritonitis secondary to icodextrin: Immunohistopathological description. Perit Dial Int 2002;22:723-726.
103. Goffin E, Scheiff JM: Transient sterile chemical peritonitis in a CAPD patient using icodextrin. Perit Dial Int 2002;22:90-91.
104. Montagnac R, Slingeneyer A, Schillinger F: Aseptic peritonitis: Role of icodextrin. Nephrol Dial Transplant 2001;16:435-436.
105. MacGinley R, Cooney K, Alexander G, Cohen S, Goldsmith DJ: Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution. Am J Kidney Dis 2002;40:1030-1035.
106. Enia G, Mandalari A, Ventura G, Pustorino D, Panuccio V: Sterile icodextrin-associated peritonitis may induce hypersensitivity and recurrent peritonitis on re-challenge. Nephrol Dial Transplant 2003;18:626.
107. Basile C, De Padova F, Montanaro A, Giordano R: The impact of relapsing sterile icodextrin-associated peritonitis on peritoneal dialysis outcome. J Nephrol 2003;16:384-386.
108. Wolfson M, Piraino B, Hamburger RJ, Morton AR: A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055-1065.
109. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC: Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14:2338-2344.